Galileo Biotech
Galileo Biotech is a multinational biopharmaceutical company dedicated to developing innovative therapies, including monoclonal antibodies and immunodiagnostic products, to address unmet medical needs such as various cancers. The company leverages cutting-edge science and technology, with a focus on immuno-oncology, and has achieved significant milestones including GMP certification for its research, development, and manufacturing workflows. It is committed to transforming patient care through advanced biotherapeutics and strategic acquisitions.
Industries
Nr. of Employees
medium (51-250)
Galileo Biotech
Av. das Américas, 12900 - B1, Loja SS 115 - Recreio dos Bandeirantes, Rio de Janeiro/RJ, Brazil
Products
Preclinical therapeutic monoclonal antibody portfolio
A pipeline of therapeutic monoclonal antibodies generated through integrated discovery and engineering workflows intended for oncology and other high-need indications.
Antibody-drug conjugates and bispecific antibody candidates
Preclinical ADCs and bispecific antibody constructs developed to provide targeted cytotoxic delivery or dual-antigen engagement for immuno-oncology applications.
Immunochemistry in-vitro diagnostic kits
Immunoassay-based diagnostic products developed and manufactured using immunochemistry workflows intended for clinical or laboratory use.
Preclinical therapeutic monoclonal antibody portfolio
A pipeline of therapeutic monoclonal antibodies generated through integrated discovery and engineering workflows intended for oncology and other high-need indications.
Antibody-drug conjugates and bispecific antibody candidates
Preclinical ADCs and bispecific antibody constructs developed to provide targeted cytotoxic delivery or dual-antigen engagement for immuno-oncology applications.
Immunochemistry in-vitro diagnostic kits
Immunoassay-based diagnostic products developed and manufactured using immunochemistry workflows intended for clinical or laboratory use.
Services
On-site GMP-certified development and manufacturing to support discovery, process development and production of investigational biologics and in-vitro diagnostic assays.
Discovery workflows combining high-throughput screening, immunization strategies, sequencing and molecular engineering to generate and advance monoclonal antibody candidates.
Development and production of immunochemistry diagnostic kits and related assays under regulated manufacturing workflows.
On-site GMP-certified development and manufacturing to support discovery, process development and production of investigational biologics and in-vitro diagnostic assays.
Discovery workflows combining high-throughput screening, immunization strategies, sequencing and molecular engineering to generate and advance monoclonal antibody candidates.
Development and production of immunochemistry diagnostic kits and related assays under regulated manufacturing workflows.
Expertise Areas
- Monoclonal antibody discovery
- Antibody engineering and humanization
- Antibody-drug conjugate (ADC) development
- Bispecific antibody development
Key Technologies
- High-throughput unbiased screening
- DNA-based immunization
- Mammalian transient expression systems
- Affinity chromatography
News & Updates
In August 2023, Antharis Therapeutics completed the acquisition of Galileo Biotech, expanding its capabilities with GMP-certified research and manufacturing facilities, and advancing its portfolio of cancer therapies.
In July 2022, Antharis Therapeutics successfully closed its Series A funding, supporting the growth and development of its pipeline of oncology immunotherapeutics.
In August 2023, Galileo Biotech, a leader in immunoassays and monoclonal antibody development in Brazil, was acquired by Antharis Therapeutics, enhancing its global research and manufacturing capabilities.
In February 2024, the company was featured in The Silicon Review for its innovative approach and robust pipeline in monoclonal antibody therapies.
In February 2024, the company received an award recognizing its advancements in monoclonal antibody therapies for oncology.
In March 2024, Dr. Ribeiro-Pinaud was recognized for his visionary leadership in biopharmaceutical innovation.
In August 2023, Antharis Therapeutics completed the acquisition of Galileo Biotech, expanding its capabilities with GMP-certified research and manufacturing facilities, and advancing its portfolio of cancer therapies.
In July 2022, Antharis Therapeutics successfully closed its Series A funding, supporting the growth and development of its pipeline of oncology immunotherapeutics.
In August 2023, Galileo Biotech, a leader in immunoassays and monoclonal antibody development in Brazil, was acquired by Antharis Therapeutics, enhancing its global research and manufacturing capabilities.
In February 2024, the company was featured in The Silicon Review for its innovative approach and robust pipeline in monoclonal antibody therapies.
In February 2024, the company received an award recognizing its advancements in monoclonal antibody therapies for oncology.
In March 2024, Dr. Ribeiro-Pinaud was recognized for his visionary leadership in biopharmaceutical innovation.